BRPI0706511A2 - marcadores de expressão genética para prognóstico de cáncer colorretal - Google Patents
marcadores de expressão genética para prognóstico de cáncer colorretal Download PDFInfo
- Publication number
- BRPI0706511A2 BRPI0706511A2 BRPI0706511-6A BRPI0706511A BRPI0706511A2 BR PI0706511 A2 BRPI0706511 A2 BR PI0706511A2 BR PI0706511 A BRPI0706511 A BR PI0706511A BR PI0706511 A2 BRPI0706511 A2 BR PI0706511A2
- Authority
- BR
- Brazil
- Prior art keywords
- expression
- evidence
- cancer
- genes
- listed
- Prior art date
Links
- 230000014509 gene expression Effects 0.000 title claims abstract description 477
- 206010009944 Colon cancer Diseases 0.000 title claims abstract description 84
- 208000001333 Colorectal Neoplasms Diseases 0.000 title claims abstract description 46
- 238000004393 prognosis Methods 0.000 title abstract description 16
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 194
- 238000000034 method Methods 0.000 claims abstract description 140
- 201000011510 cancer Diseases 0.000 claims abstract description 134
- 239000012472 biological sample Substances 0.000 claims abstract description 45
- 108090000623 proteins and genes Proteins 0.000 claims description 243
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 97
- 230000004083 survival effect Effects 0.000 claims description 72
- 238000002271 resection Methods 0.000 claims description 51
- 208000029742 colonic neoplasm Diseases 0.000 claims description 48
- 201000010099 disease Diseases 0.000 claims description 44
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 44
- 230000002829 reductive effect Effects 0.000 claims description 28
- 238000001356 surgical procedure Methods 0.000 claims description 25
- -1 CENPE1 CLTC1CYR61 Proteins 0.000 claims description 21
- 102100026425 Adhesion G protein-coupled receptor E3 Human genes 0.000 claims description 16
- 102100037982 Alpha-1,6-mannosylglycoprotein 6-beta-N-acetylglucosaminyltransferase A Human genes 0.000 claims description 16
- 108700020472 CDC20 Proteins 0.000 claims description 16
- 101150023302 Cdc20 gene Proteins 0.000 claims description 16
- 101000718235 Homo sapiens Adhesion G protein-coupled receptor E3 Proteins 0.000 claims description 16
- 101000951392 Homo sapiens Alpha-1,6-mannosylglycoprotein 6-beta-N-acetylglucosaminyltransferase A Proteins 0.000 claims description 16
- 101000599858 Homo sapiens Intercellular adhesion molecule 2 Proteins 0.000 claims description 16
- 101000835877 Homo sapiens Mothers against decapentaplegic homolog 2 Proteins 0.000 claims description 16
- 101000884271 Homo sapiens Signal transducer CD24 Proteins 0.000 claims description 16
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims description 16
- 102100037872 Intercellular adhesion molecule 2 Human genes 0.000 claims description 16
- 102100025751 Mothers against decapentaplegic homolog 2 Human genes 0.000 claims description 16
- 101000654471 Mus musculus NAD-dependent protein deacetylase sirtuin-1 Proteins 0.000 claims description 16
- 101100010298 Schizosaccharomyces pombe (strain 972 / ATCC 24843) pol2 gene Proteins 0.000 claims description 16
- 102100038081 Signal transducer CD24 Human genes 0.000 claims description 16
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims description 16
- QYAPHLRPFNSDNH-MRFRVZCGSA-N (4s,4as,5as,6s,12ar)-7-chloro-4-(dimethylamino)-1,6,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4,4a,5,5a-tetrahydrotetracene-2-carboxamide;hydrochloride Chemical compound Cl.C1=CC(Cl)=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]4(O)C(=O)C3=C(O)C2=C1O QYAPHLRPFNSDNH-MRFRVZCGSA-N 0.000 claims description 15
- 102100024155 Cadherin-11 Human genes 0.000 claims description 15
- 102100026127 Clathrin heavy chain 1 Human genes 0.000 claims description 15
- 102100030074 Dickkopf-related protein 1 Human genes 0.000 claims description 15
- 101000762236 Homo sapiens Cadherin-11 Proteins 0.000 claims description 15
- 101000912851 Homo sapiens Clathrin heavy chain 1 Proteins 0.000 claims description 15
- 101000864646 Homo sapiens Dickkopf-related protein 1 Proteins 0.000 claims description 15
- 101000760817 Homo sapiens Macrophage-capping protein Proteins 0.000 claims description 15
- 101000990912 Homo sapiens Matrilysin Proteins 0.000 claims description 15
- 101000590492 Homo sapiens Nuclear fragile X mental retardation-interacting protein 1 Proteins 0.000 claims description 15
- 101000658157 Homo sapiens Thymosin beta-4 Proteins 0.000 claims description 15
- 101710159002 L-lactate oxidase Proteins 0.000 claims description 15
- 102100024573 Macrophage-capping protein Human genes 0.000 claims description 15
- 102100030417 Matrilysin Human genes 0.000 claims description 15
- 102100032428 Nuclear fragile X mental retardation-interacting protein 1 Human genes 0.000 claims description 15
- 102100026858 Protein-lysine 6-oxidase Human genes 0.000 claims description 15
- 101150063267 STAT5B gene Proteins 0.000 claims description 15
- 102100024474 Signal transducer and activator of transcription 5B Human genes 0.000 claims description 15
- 102100035000 Thymosin beta-4 Human genes 0.000 claims description 15
- 108010078184 Trefoil Factor-3 Proteins 0.000 claims description 15
- 102100022586 17-beta-hydroxysteroid dehydrogenase type 2 Human genes 0.000 claims description 14
- 102100025832 Centromere-associated protein E Human genes 0.000 claims description 14
- 102100034501 Cyclin-dependent kinases regulatory subunit 1 Human genes 0.000 claims description 14
- 108010019961 Cysteine-Rich Protein 61 Proteins 0.000 claims description 14
- 102000005889 Cysteine-Rich Protein 61 Human genes 0.000 claims description 14
- 101001045223 Homo sapiens 17-beta-hydroxysteroid dehydrogenase type 2 Proteins 0.000 claims description 14
- 101000914247 Homo sapiens Centromere-associated protein E Proteins 0.000 claims description 14
- 101000710200 Homo sapiens Cyclin-dependent kinases regulatory subunit 1 Proteins 0.000 claims description 14
- 101000619805 Homo sapiens Peroxiredoxin-5, mitochondrial Proteins 0.000 claims description 14
- 101000619708 Homo sapiens Peroxiredoxin-6 Proteins 0.000 claims description 14
- 102100022078 Peroxiredoxin-5, mitochondrial Human genes 0.000 claims description 14
- 102000000504 Tumor Suppressor p53-Binding Protein 1 Human genes 0.000 claims description 12
- 108010041385 Tumor Suppressor p53-Binding Protein 1 Proteins 0.000 claims description 12
- 102000040650 (ribonucleotides)n+m Human genes 0.000 claims description 8
- 101100404726 Arabidopsis thaliana NHX7 gene Proteins 0.000 claims description 8
- 102000057028 SOS1 Human genes 0.000 claims description 8
- 108700022176 SOS1 Proteins 0.000 claims description 8
- 101100197320 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) RPL35A gene Proteins 0.000 claims description 8
- 101150100839 Sos1 gene Proteins 0.000 claims description 8
- 238000002512 chemotherapy Methods 0.000 claims description 8
- 238000002560 therapeutic procedure Methods 0.000 claims description 4
- 238000011374 additional therapy Methods 0.000 claims description 2
- 231100000357 carcinogen Toxicity 0.000 claims description 2
- 239000003183 carcinogenic agent Substances 0.000 claims description 2
- 238000001959 radiotherapy Methods 0.000 claims description 2
- 102000028756 CDC20 Human genes 0.000 claims 7
- 102000014456 Trefoil Factor-3 Human genes 0.000 claims 7
- 101000665937 Homo sapiens Wnt inhibitory factor 1 Proteins 0.000 claims 1
- 101150106914 LOX1 gene Proteins 0.000 claims 1
- 101150014436 LOX1.1 gene Proteins 0.000 claims 1
- 101150086211 OLR1 gene Proteins 0.000 claims 1
- 102100025386 Oxidized low-density lipoprotein receptor 1 Human genes 0.000 claims 1
- 101100455173 Phaseolus vulgaris LOXA gene Proteins 0.000 claims 1
- 108010029477 STAT5 Transcription Factor Proteins 0.000 claims 1
- 102100024481 Signal transducer and activator of transcription 5A Human genes 0.000 claims 1
- 101100182222 Solanum tuberosum LOX1.2 gene Proteins 0.000 claims 1
- 102100038258 Wnt inhibitory factor 1 Human genes 0.000 claims 1
- 230000002068 genetic effect Effects 0.000 abstract description 23
- 239000000047 product Substances 0.000 description 90
- 210000004027 cell Anatomy 0.000 description 51
- 230000000875 corresponding effect Effects 0.000 description 50
- 238000004458 analytical method Methods 0.000 description 49
- 239000000523 sample Substances 0.000 description 40
- 108020004414 DNA Proteins 0.000 description 36
- 210000001519 tissue Anatomy 0.000 description 31
- 238000011282 treatment Methods 0.000 description 24
- 239000013615 primer Substances 0.000 description 22
- 238000012360 testing method Methods 0.000 description 21
- 210000001072 colon Anatomy 0.000 description 19
- 108020004999 messenger RNA Proteins 0.000 description 17
- 208000015634 Rectal Neoplasms Diseases 0.000 description 16
- 238000000611 regression analysis Methods 0.000 description 15
- 238000012340 reverse transcriptase PCR Methods 0.000 description 15
- 238000006243 chemical reaction Methods 0.000 description 13
- 229940079593 drug Drugs 0.000 description 13
- 239000003814 drug Substances 0.000 description 13
- 102000040430 polynucleotide Human genes 0.000 description 13
- 108091033319 polynucleotide Proteins 0.000 description 13
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 12
- 239000002299 complementary DNA Substances 0.000 description 12
- 229960002949 fluorouracil Drugs 0.000 description 12
- 238000009396 hybridization Methods 0.000 description 12
- 239000002157 polynucleotide Substances 0.000 description 12
- 238000012163 sequencing technique Methods 0.000 description 12
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 11
- 230000003321 amplification Effects 0.000 description 11
- 230000001276 controlling effect Effects 0.000 description 11
- 230000000694 effects Effects 0.000 description 11
- 238000003199 nucleic acid amplification method Methods 0.000 description 11
- 102000004169 proteins and genes Human genes 0.000 description 11
- 210000004881 tumor cell Anatomy 0.000 description 11
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 10
- 230000011987 methylation Effects 0.000 description 10
- 238000007069 methylation reaction Methods 0.000 description 10
- 108091093088 Amplicon Proteins 0.000 description 9
- 102100038099 Cell division cycle protein 20 homolog Human genes 0.000 description 9
- 239000003153 chemical reaction reagent Substances 0.000 description 9
- 238000010195 expression analysis Methods 0.000 description 9
- 210000001165 lymph node Anatomy 0.000 description 9
- 238000002493 microarray Methods 0.000 description 9
- 238000000491 multivariate analysis Methods 0.000 description 9
- 108091034117 Oligonucleotide Proteins 0.000 description 8
- 102100039145 Trefoil factor 3 Human genes 0.000 description 8
- 230000008901 benefit Effects 0.000 description 8
- 230000003993 interaction Effects 0.000 description 8
- 238000013459 approach Methods 0.000 description 7
- 238000013461 design Methods 0.000 description 7
- 239000003550 marker Substances 0.000 description 7
- 230000034994 death Effects 0.000 description 6
- 231100000517 death Toxicity 0.000 description 6
- 239000000975 dye Substances 0.000 description 6
- 238000010606 normalization Methods 0.000 description 6
- 230000035790 physiological processes and functions Effects 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 238000000746 purification Methods 0.000 description 6
- 206010038038 rectal cancer Diseases 0.000 description 6
- 201000001275 rectum cancer Diseases 0.000 description 6
- 238000010839 reverse transcription Methods 0.000 description 6
- 239000011780 sodium chloride Substances 0.000 description 6
- VVIAGPKUTFNRDU-UHFFFAOYSA-N 6S-folinic acid Natural products C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-UHFFFAOYSA-N 0.000 description 5
- 102000053602 DNA Human genes 0.000 description 5
- 102100031780 Endonuclease Human genes 0.000 description 5
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 5
- 206010027476 Metastases Diseases 0.000 description 5
- 241001467552 Mycobacterium bovis BCG Species 0.000 description 5
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 5
- 229960000190 bacillus calmette–guérin vaccine Drugs 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- VVIAGPKUTFNRDU-ABLWVSNPSA-N folinic acid Chemical compound C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-ABLWVSNPSA-N 0.000 description 5
- 235000008191 folinic acid Nutrition 0.000 description 5
- 239000011672 folinic acid Substances 0.000 description 5
- 229960001691 leucovorin Drugs 0.000 description 5
- 230000009401 metastasis Effects 0.000 description 5
- 239000002773 nucleotide Substances 0.000 description 5
- 210000000056 organ Anatomy 0.000 description 5
- 239000012188 paraffin wax Substances 0.000 description 5
- 230000002980 postoperative effect Effects 0.000 description 5
- 238000003196 serial analysis of gene expression Methods 0.000 description 5
- 239000001509 sodium citrate Substances 0.000 description 5
- JZZPZVLDDWYVLE-UHFFFAOYSA-N 1-hydroxydecan-2-one Chemical compound CCCCCCCCC(=O)CO JZZPZVLDDWYVLE-UHFFFAOYSA-N 0.000 description 4
- 206010006187 Breast cancer Diseases 0.000 description 4
- 208000026310 Breast neoplasm Diseases 0.000 description 4
- 108700024394 Exon Proteins 0.000 description 4
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 4
- 108091092195 Intron Proteins 0.000 description 4
- 238000002123 RNA extraction Methods 0.000 description 4
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 4
- 238000011529 RT qPCR Methods 0.000 description 4
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000009274 differential gene expression Effects 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 239000012634 fragment Substances 0.000 description 4
- 230000000968 intestinal effect Effects 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 125000003729 nucleotide group Chemical group 0.000 description 4
- 230000007170 pathology Effects 0.000 description 4
- 239000002987 primer (paints) Substances 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 238000012216 screening Methods 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- 231100000331 toxic Toxicity 0.000 description 4
- 230000002588 toxic effect Effects 0.000 description 4
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 3
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 3
- 108020004635 Complementary DNA Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 101710163270 Nuclease Proteins 0.000 description 3
- 108010006785 Taq Polymerase Proteins 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 210000000481 breast Anatomy 0.000 description 3
- 238000004364 calculation method Methods 0.000 description 3
- 230000004663 cell proliferation Effects 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 238000007405 data analysis Methods 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 238000009509 drug development Methods 0.000 description 3
- 210000002919 epithelial cell Anatomy 0.000 description 3
- 102000006602 glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 3
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 239000003999 initiator Substances 0.000 description 3
- 230000009545 invasion Effects 0.000 description 3
- 238000010841 mRNA extraction Methods 0.000 description 3
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 description 3
- 229960001756 oxaliplatin Drugs 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- 241000972773 Aulopiformes Species 0.000 description 2
- 239000003298 DNA probe Substances 0.000 description 2
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 2
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 2
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 2
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
- 108091027974 Mature messenger RNA Proteins 0.000 description 2
- 102100031911 NEDD8 Human genes 0.000 description 2
- 108700004934 NEDD8 Proteins 0.000 description 2
- 101150107958 NEDD8 gene Proteins 0.000 description 2
- 206010061309 Neoplasm progression Diseases 0.000 description 2
- 101100532088 Oryza sativa subsp. japonica RUB2 gene Proteins 0.000 description 2
- 101100532090 Oryza sativa subsp. japonica RUB3 gene Proteins 0.000 description 2
- 238000010802 RNA extraction kit Methods 0.000 description 2
- 108020004682 Single-Stranded DNA Proteins 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 238000009098 adjuvant therapy Methods 0.000 description 2
- 230000008033 biological extinction Effects 0.000 description 2
- 230000005773 cancer-related death Effects 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 210000002808 connective tissue Anatomy 0.000 description 2
- 230000001186 cumulative effect Effects 0.000 description 2
- 238000005520 cutting process Methods 0.000 description 2
- 229960000633 dextran sulfate Drugs 0.000 description 2
- 238000002405 diagnostic procedure Methods 0.000 description 2
- 230000007717 exclusion Effects 0.000 description 2
- 239000007850 fluorescent dye Substances 0.000 description 2
- 229960002897 heparin Drugs 0.000 description 2
- 229920000669 heparin Polymers 0.000 description 2
- 229940022353 herceptin Drugs 0.000 description 2
- 238000009169 immunotherapy Methods 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 208000014018 liver neoplasm Diseases 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 230000009826 neoplastic cell growth Effects 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 239000013610 patient sample Substances 0.000 description 2
- 238000003752 polymerase chain reaction Methods 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 238000004445 quantitative analysis Methods 0.000 description 2
- 210000000664 rectum Anatomy 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000007634 remodeling Methods 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 230000003252 repetitive effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 101150024074 rub1 gene Proteins 0.000 description 2
- 235000019515 salmon Nutrition 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000001488 sodium phosphate Substances 0.000 description 2
- 229910000162 sodium phosphate Inorganic materials 0.000 description 2
- 238000000551 statistical hypothesis test Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 2
- 230000005751 tumor progression Effects 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 101150028074 2 gene Proteins 0.000 description 1
- 102100026357 40S ribosomal protein S13 Human genes 0.000 description 1
- LRSASMSXMSNRBT-UHFFFAOYSA-N 5-methylcytosine Chemical group CC1=CNC(=O)N=C1N LRSASMSXMSNRBT-UHFFFAOYSA-N 0.000 description 1
- 102100022961 ATP synthase subunit epsilon, mitochondrial Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 102100034613 Annexin A2 Human genes 0.000 description 1
- 102100021253 Antileukoproteinase Human genes 0.000 description 1
- 108020005544 Antisense RNA Proteins 0.000 description 1
- 101000693933 Arabidopsis thaliana Fructose-bisphosphate aldolase 8, cytosolic Proteins 0.000 description 1
- 102000036365 BRCA1 Human genes 0.000 description 1
- 108700020463 BRCA1 Proteins 0.000 description 1
- 101150072950 BRCA1 gene Proteins 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 102100021943 C-C motif chemokine 2 Human genes 0.000 description 1
- 101100497948 Caenorhabditis elegans cyn-1 gene Proteins 0.000 description 1
- 102100024436 Caldesmon Human genes 0.000 description 1
- 241000252229 Carassius auratus Species 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 108090000994 Catalytic RNA Proteins 0.000 description 1
- 102000053642 Catalytic RNA Human genes 0.000 description 1
- 102100021633 Cathepsin B Human genes 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 108010077544 Chromatin Proteins 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 102100033601 Collagen alpha-1(I) chain Human genes 0.000 description 1
- 102100036213 Collagen alpha-2(I) chain Human genes 0.000 description 1
- 108091035707 Consensus sequence Proteins 0.000 description 1
- 108091029523 CpG island Proteins 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 238000000018 DNA microarray Methods 0.000 description 1
- 239000003155 DNA primer Substances 0.000 description 1
- 241000238557 Decapoda Species 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 102100037573 Dual specificity protein phosphatase 12 Human genes 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 102100023226 Early growth response protein 1 Human genes 0.000 description 1
- 102100021717 Early growth response protein 3 Human genes 0.000 description 1
- 108010042407 Endonucleases Proteins 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 229920001917 Ficoll Polymers 0.000 description 1
- 240000008168 Ficus benjamina Species 0.000 description 1
- MPJKWIXIYCLVCU-UHFFFAOYSA-N Folinic acid Natural products NC1=NC2=C(N(C=O)C(CNc3ccc(cc3)C(=O)NC(CCC(=O)O)CC(=O)O)CN2)C(=O)N1 MPJKWIXIYCLVCU-UHFFFAOYSA-N 0.000 description 1
- 102100039799 Frizzled-6 Human genes 0.000 description 1
- 102100037854 G1/S-specific cyclin-E2 Human genes 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102100033039 Glutathione peroxidase 1 Human genes 0.000 description 1
- 101150054472 HER2 gene Proteins 0.000 description 1
- 101000718313 Homo sapiens 40S ribosomal protein S13 Proteins 0.000 description 1
- 101000975151 Homo sapiens ATP synthase subunit epsilon, mitochondrial Proteins 0.000 description 1
- 101000924474 Homo sapiens Annexin A2 Proteins 0.000 description 1
- 101000615334 Homo sapiens Antileukoproteinase Proteins 0.000 description 1
- 101000910297 Homo sapiens Caldesmon Proteins 0.000 description 1
- 101000898449 Homo sapiens Cathepsin B Proteins 0.000 description 1
- 101000875067 Homo sapiens Collagen alpha-2(I) chain Proteins 0.000 description 1
- 101000924017 Homo sapiens Dual specificity protein phosphatase 1 Proteins 0.000 description 1
- 101000881110 Homo sapiens Dual specificity protein phosphatase 12 Proteins 0.000 description 1
- 101001049697 Homo sapiens Early growth response protein 1 Proteins 0.000 description 1
- 101000896450 Homo sapiens Early growth response protein 3 Proteins 0.000 description 1
- 101000885673 Homo sapiens Frizzled-6 Proteins 0.000 description 1
- 101000738575 Homo sapiens G1/S-specific cyclin-E2 Proteins 0.000 description 1
- 101001014936 Homo sapiens Glutathione peroxidase 1 Proteins 0.000 description 1
- 101000605522 Homo sapiens Kallikrein-1 Proteins 0.000 description 1
- 101001008919 Homo sapiens Kallikrein-10 Proteins 0.000 description 1
- 101001091385 Homo sapiens Kallikrein-6 Proteins 0.000 description 1
- 101001023271 Homo sapiens Laminin subunit gamma-2 Proteins 0.000 description 1
- 101000934372 Homo sapiens Macrosialin Proteins 0.000 description 1
- 101001109700 Homo sapiens Nuclear receptor subfamily 4 group A member 1 Proteins 0.000 description 1
- 101000579123 Homo sapiens Phosphoglycerate kinase 1 Proteins 0.000 description 1
- 101000772905 Homo sapiens Polyubiquitin-B Proteins 0.000 description 1
- 101000861454 Homo sapiens Protein c-Fos Proteins 0.000 description 1
- 101000777293 Homo sapiens Serine/threonine-protein kinase Chk1 Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 229930010555 Inosine Natural products 0.000 description 1
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 1
- 102100027613 Kallikrein-10 Human genes 0.000 description 1
- 102100034866 Kallikrein-6 Human genes 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- 102100022743 Laminin subunit alpha-4 Human genes 0.000 description 1
- 102100035159 Laminin subunit gamma-2 Human genes 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 208000007433 Lymphatic Metastasis Diseases 0.000 description 1
- 241001082241 Lythrum hyssopifolia Species 0.000 description 1
- 102100025136 Macrosialin Human genes 0.000 description 1
- 101710091439 Major capsid protein 1 Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 108700019961 Neoplasm Genes Proteins 0.000 description 1
- 102000048850 Neoplasm Genes Human genes 0.000 description 1
- 238000000636 Northern blotting Methods 0.000 description 1
- 102100022679 Nuclear receptor subfamily 4 group A member 1 Human genes 0.000 description 1
- 208000035327 Oestrogen receptor positive breast cancer Diseases 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 238000009004 PCR Kit Methods 0.000 description 1
- KJWZYMMLVHIVSU-IYCNHOCDSA-N PGK1 Chemical compound CCCCC[C@H](O)\C=C\[C@@H]1[C@@H](CCCCCCC(O)=O)C(=O)CC1=O KJWZYMMLVHIVSU-IYCNHOCDSA-N 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 102100028251 Phosphoglycerate kinase 1 Human genes 0.000 description 1
- 102100030432 Polyubiquitin-B Human genes 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102100027584 Protein c-Fos Human genes 0.000 description 1
- 108010026552 Proteome Proteins 0.000 description 1
- 238000010240 RT-PCR analysis Methods 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 238000012952 Resampling Methods 0.000 description 1
- 102100027611 Rho-related GTP-binding protein RhoB Human genes 0.000 description 1
- 101150054980 Rhob gene Proteins 0.000 description 1
- 108091028664 Ribonucleotide Proteins 0.000 description 1
- 108010055623 S-Phase Kinase-Associated Proteins Proteins 0.000 description 1
- 102000000341 S-Phase Kinase-Associated Proteins Human genes 0.000 description 1
- 108010005173 SERPIN-B5 Proteins 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 208000003837 Second Primary Neoplasms Diseases 0.000 description 1
- 102100031081 Serine/threonine-protein kinase Chk1 Human genes 0.000 description 1
- 102100030333 Serpin B5 Human genes 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 101000879712 Streptomyces lividans Protease inhibitor Proteins 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- 241000241899 Trechodes Species 0.000 description 1
- 108010078814 Tumor Suppressor Protein p53 Proteins 0.000 description 1
- 102000015098 Tumor Suppressor Protein p53 Human genes 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 238000011226 adjuvant chemotherapy Methods 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 108010029483 alpha 1 Chain Collagen Type I Proteins 0.000 description 1
- 238000005267 amalgamation Methods 0.000 description 1
- 239000012491 analyte Substances 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 238000002306 biochemical method Methods 0.000 description 1
- 238000003766 bioinformatics method Methods 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 239000012888 bovine serum Substances 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 238000010366 cell biology technique Methods 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 210000003483 chromatin Anatomy 0.000 description 1
- 238000007621 cluster analysis Methods 0.000 description 1
- 201000010897 colon adenocarcinoma Diseases 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 239000003184 complementary RNA Substances 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 238000010219 correlation analysis Methods 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 description 1
- SUYVUBYJARFZHO-UHFFFAOYSA-N dATP Natural products C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-UHFFFAOYSA-N 0.000 description 1
- RGWHQCVHVJXOKC-SHYZEUOFSA-J dCTP(4-) Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-J 0.000 description 1
- HAAZLUGHYHWQIW-KVQBGUIXSA-N dGTP Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 HAAZLUGHYHWQIW-KVQBGUIXSA-N 0.000 description 1
- NHVNXKFIZYSCEB-XLPZGREQSA-N dTTP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C1 NHVNXKFIZYSCEB-XLPZGREQSA-N 0.000 description 1
- 238000000432 density-gradient centrifugation Methods 0.000 description 1
- 239000005547 deoxyribonucleotide Substances 0.000 description 1
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
- 230000030609 dephosphorylation Effects 0.000 description 1
- 238000006209 dephosphorylation reaction Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 1
- 229940043264 dodecyl sulfate Drugs 0.000 description 1
- 238000007877 drug screening Methods 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 108700020302 erbB-2 Genes Proteins 0.000 description 1
- 201000007281 estrogen-receptor positive breast cancer Diseases 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 235000019688 fish Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 238000011223 gene expression profiling Methods 0.000 description 1
- 230000030279 gene silencing Effects 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 238000009499 grossing Methods 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 230000006195 histone acetylation Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000002055 immunohistochemical effect Effects 0.000 description 1
- 238000012151 immunohistochemical method Methods 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 238000007901 in situ hybridization Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229960003786 inosine Drugs 0.000 description 1
- 238000005304 joining Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 108010008094 laminin alpha 3 Proteins 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 238000012886 linear function Methods 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 201000010453 lymph node cancer Diseases 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000000816 matrix-assisted laser desorption--ionisation Methods 0.000 description 1
- 238000001840 matrix-assisted laser desorption--ionisation time-of-flight mass spectrometry Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 238000007855 methylation-specific PCR Methods 0.000 description 1
- 238000010208 microarray analysis Methods 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 238000002515 oligonucleotide synthesis Methods 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 210000003240 portal vein Anatomy 0.000 description 1
- 238000011248 postoperative chemotherapy Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000001915 proofreading effect Effects 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 230000004952 protein activity Effects 0.000 description 1
- 238000000575 proteomic method Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- XKMLYUALXHKNFT-UHFFFAOYSA-N rGTP Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O XKMLYUALXHKNFT-UHFFFAOYSA-N 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 230000022983 regulation of cell cycle Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 239000002336 ribonucleotide Substances 0.000 description 1
- 125000002652 ribonucleotide group Chemical group 0.000 description 1
- 108091092562 ribozyme Proteins 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- FQENQNTWSFEDLI-UHFFFAOYSA-J sodium diphosphate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]P([O-])(=O)OP([O-])([O-])=O FQENQNTWSFEDLI-UHFFFAOYSA-J 0.000 description 1
- 229940048086 sodium pyrophosphate Drugs 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000011255 standard chemotherapy Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 210000002536 stromal cell Anatomy 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000011477 surgical intervention Methods 0.000 description 1
- 210000004876 tela submucosa Anatomy 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 235000019818 tetrasodium diphosphate Nutrition 0.000 description 1
- 239000001577 tetrasodium phosphonato phosphate Substances 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 201000002510 thyroid cancer Diseases 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 238000011277 treatment modality Methods 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 239000001226 triphosphate Substances 0.000 description 1
- 235000011178 triphosphate Nutrition 0.000 description 1
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 1
- 229940038773 trisodium citrate Drugs 0.000 description 1
- 238000007473 univariate analysis Methods 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 210000001635 urinary tract Anatomy 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 230000036642 wellbeing Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57419—Specifically defined cancers of colon
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57446—Specifically defined cancers of stomach or intestine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Cell Biology (AREA)
- General Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- Food Science & Technology (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US75839206P | 2006-01-11 | 2006-01-11 | |
| US60/758,392 | 2006-01-11 | ||
| US80027706P | 2006-05-12 | 2006-05-12 | |
| US60/800,277 | 2006-05-12 | ||
| US81007706P | 2006-05-31 | 2006-05-31 | |
| US60/810,077 | 2006-05-31 | ||
| PCT/US2007/000995 WO2007082099A2 (en) | 2006-01-11 | 2007-01-11 | Gene expression markers for colorectal cancer prognosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0706511A2 true BRPI0706511A2 (pt) | 2011-03-29 |
Family
ID=38257063
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0706511-6A BRPI0706511A2 (pt) | 2006-01-11 | 2007-01-11 | marcadores de expressão genética para prognóstico de cáncer colorretal |
Country Status (14)
| Country | Link |
|---|---|
| US (10) | US7695913B2 (enExample) |
| EP (9) | EP2412824B1 (enExample) |
| JP (7) | JP5297202B2 (enExample) |
| KR (1) | KR20090003178A (enExample) |
| AU (1) | AU2007204826B2 (enExample) |
| BR (1) | BRPI0706511A2 (enExample) |
| CA (1) | CA2636984A1 (enExample) |
| DK (1) | DK1974058T3 (enExample) |
| ES (1) | ES2491222T3 (enExample) |
| IL (1) | IL192794A (enExample) |
| MX (1) | MX2008008973A (enExample) |
| NO (1) | NO20083461L (enExample) |
| NZ (7) | NZ593224A (enExample) |
| WO (1) | WO2007082099A2 (enExample) |
Families Citing this family (81)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2506066A1 (en) | 2002-11-15 | 2004-06-03 | Genomic Health, Inc. | Gene expression profiling of egfr positive cancer |
| CA2848463A1 (en) | 2004-04-09 | 2005-10-27 | Genomic Health, Inc. | Gene expression markers for predicting response to chemotherapy |
| KR20090003178A (ko) * | 2006-01-11 | 2009-01-09 | 게노믹 헬쓰, 인코포레이티드 | 직장결장암 예후에 대한 유전자 발현 마커 |
| US8768629B2 (en) * | 2009-02-11 | 2014-07-01 | Caris Mpi, Inc. | Molecular profiling of tumors |
| BRPI0711011A2 (pt) | 2006-05-18 | 2011-08-23 | Molecular Profiling Inst Inc | método para a determinação da intervenção médica para um estado de doença, método para a identificação de uma terapia de droga com capacidade de interação com um alvo molecular e sistema para a determinação da intervenção médica individualizada para um estado de doença |
| US20090076734A1 (en) | 2007-03-22 | 2009-03-19 | Torres-Roca Javier F | Gene Signature for the Prediction of Radiation Therapy Response |
| US20080234946A1 (en) * | 2007-03-22 | 2008-09-25 | University Of South Florida | Predictive radiosensitivity network model |
| WO2008117067A2 (en) | 2007-03-27 | 2008-10-02 | Carl Arne Krister Borrebaeck | Protein signature/markers for the detection of adenocarcinoma |
| US20090123920A1 (en) * | 2007-11-08 | 2009-05-14 | Maher Albitar | Jak2 mutations |
| ES2332167B1 (es) | 2007-12-04 | 2010-10-25 | Universidad Autonoma De Madrid | Empleo de trefoil factor-family 3 (tff3) en el pronostico de sujetos diagnosticados con cancer colorectal. |
| WO2009123634A1 (en) * | 2008-04-02 | 2009-10-08 | Regents Of The University Of California | Systems and methods for predicting response of biological samples |
| US8067178B2 (en) | 2008-03-14 | 2011-11-29 | Genomic Health, Inc. | Gene expression markers for prediction of patient response to chemotherapy |
| AU2009246398A1 (en) | 2008-05-14 | 2009-11-19 | Bristol-Myers Squibb Company | Predictors of patient response to treatment with EGF receptor inhibitors |
| US20100029748A1 (en) * | 2008-08-04 | 2010-02-04 | Sloan-Kettering Institute For Cancer Research | Metastasis Promoting Genes and Proteins |
| US10359425B2 (en) * | 2008-09-09 | 2019-07-23 | Somalogic, Inc. | Lung cancer biomarkers and uses thereof |
| US20100221752A2 (en) * | 2008-10-06 | 2010-09-02 | Somalogic, Inc. | Ovarian Cancer Biomarkers and Uses Thereof |
| WO2010042228A2 (en) * | 2008-10-10 | 2010-04-15 | Cornell University | Methods for predicting disease outcome in patients with colon cancer |
| US20120041274A1 (en) | 2010-01-07 | 2012-02-16 | Myriad Genetics, Incorporated | Cancer biomarkers |
| US8765383B2 (en) | 2009-04-07 | 2014-07-01 | Genomic Health, Inc. | Methods of predicting cancer risk using gene expression in premalignant tissue |
| WO2010127322A1 (en) * | 2009-05-01 | 2010-11-04 | Genomic Health Inc. | Gene expression profile algorithm and test for likelihood of recurrence of colorectal cancer and response to chemotherapy |
| TWI513465B (zh) * | 2009-06-25 | 2015-12-21 | Regeneron Pharma | 以ｄｌｌ４拮抗劑與化學治療劑治療癌症之方法 |
| EP3812469A1 (en) | 2010-07-07 | 2021-04-28 | Myriad Genetics, Inc. | Gene signatures for cancer prognosis |
| MX355020B (es) | 2010-07-09 | 2018-04-02 | Somalogic Inc | Biomarcadores de cancer de pulmon y usos de los mismos. |
| MX338883B (es) | 2010-07-27 | 2016-05-04 | Genomic Health Inc | Metodo para usar expresion de gen para determinar el pronostico de cancer de prostata. |
| JP5931874B2 (ja) | 2010-08-13 | 2016-06-08 | ソマロジック・インコーポレーテッド | 膵癌バイオマーカーおよびその使用 |
| WO2012030840A2 (en) | 2010-08-30 | 2012-03-08 | Myriad Genetics, Inc. | Gene signatures for cancer diagnosis and prognosis |
| CN106978480A (zh) | 2010-09-15 | 2017-07-25 | 阿尔玛克诊断有限公司 | 用于癌症的分子诊断试验 |
| AU2012209074A1 (en) * | 2011-01-25 | 2013-07-11 | Almac Diagnostics Limited | Colon cancer gene expression signatures and methods of use |
| US10308980B2 (en) | 2011-11-04 | 2019-06-04 | Oslo Universitetssykehus Hf | Methods and biomarkers for analysis of colorectal cancer |
| AU2012344155A1 (en) | 2011-11-28 | 2014-07-03 | Fundacio Institut De Recerca Biomedica (Irb Barcelona) | Methods and kits for the prognosis of colorectal cancer |
| EP2794924B1 (en) | 2011-12-22 | 2019-02-06 | Baylor Research Institute | Identification of mirna signatures in human colorectal cancer |
| US9822417B2 (en) | 2012-01-09 | 2017-11-21 | Oslo Universitetssykehus Hf | Methods and biomarkers for analysis of colorectal cancer |
| SG11201404390WA (en) | 2012-01-31 | 2014-08-28 | Genomic Health Inc | Gene expression profile algorithm and test for determining prognosis of prostate cancer |
| WO2013150167A2 (es) | 2012-04-03 | 2013-10-10 | Servicio Andaluz De Salud | Modelo de expresión de microarn como indicador de supervivencia en pacientes de cancer colorrectal metastásico |
| US20160222457A1 (en) * | 2012-11-14 | 2016-08-04 | Mayo Foundation For Medical Education And Research | Methods and materials for identifying malignant skin lesions |
| WO2014078700A1 (en) | 2012-11-16 | 2014-05-22 | Myriad Genetics, Inc. | Gene signatures for cancer prognosis |
| ES2475366B1 (es) * | 2012-12-10 | 2015-05-05 | Fundación Imdea Alimentación | Métodos y kits para el pronóstico del cáncer colorrectal |
| WO2014159797A1 (en) | 2013-03-14 | 2014-10-02 | Abbott Molecular Inc. | Cell preparations and cell supports and their use in theranosis |
| WO2014191559A1 (en) * | 2013-05-30 | 2014-12-04 | Institució Catalana De Recerca I Estudis Avançats | Methods and kits for the prognosis of colorectal cancer |
| US10185809B1 (en) * | 2013-10-15 | 2019-01-22 | Iqvia Inc. | Patient projection methodology |
| GB201319878D0 (en) * | 2013-11-11 | 2013-12-25 | Immunovia Ab | Method, Array and use thereof |
| AU2015237229A1 (en) * | 2014-03-28 | 2016-11-10 | Applied Proteomics, Inc. | Protein biomarker profiles for detecting colorectal tumors |
| EP3143160B1 (en) | 2014-05-13 | 2019-11-06 | Myriad Genetics, Inc. | Gene signatures for cancer prognosis |
| US20170275700A1 (en) | 2014-08-14 | 2017-09-28 | Mayo Foundation For Medical Education And Research | Methods and materials for identifying metastatic malignant skin lesions and treating skin cancer |
| US10184154B2 (en) | 2014-09-26 | 2019-01-22 | Mayo Foundation For Medical Education And Research | Detecting cholangiocarcinoma |
| WO2016062892A1 (en) | 2014-10-24 | 2016-04-28 | Koninklijke Philips N.V. | Medical prognosis and prediction of treatment response using multiple cellular signaling pathway activities |
| AU2015334842B2 (en) | 2014-10-24 | 2022-02-17 | Koninklijke Philips N.V. | Medical prognosis and prediction of treatment response using multiple cellular signaling pathway activities |
| CN107077536B (zh) | 2014-10-24 | 2021-09-28 | 皇家飞利浦有限公司 | 使用靶基因表达的数学建模评价TGF-β细胞信号传导途径的活性 |
| DE112014007209T5 (de) | 2014-11-25 | 2017-08-03 | Mitsubishi Electric Corporation | Pneumatischer Antrieb |
| US20180148789A1 (en) * | 2014-12-01 | 2018-05-31 | University Of Southern California | Methods for treating and assessing tumor invasion and metastasis |
| CN107532124B (zh) | 2015-03-27 | 2022-08-09 | 精密科学公司 | 检测食管疾病 |
| EP3073268A1 (en) * | 2015-03-27 | 2016-09-28 | Deutsches Krebsforschungszentrum Stiftung des Öffentlichen Rechts | Biomarker panel for diagnosing cancer |
| GB2545361B (en) | 2015-04-10 | 2018-01-24 | Applied Proteomics Inc | Methods of assessing colorectal cancer status |
| CN108271422A (zh) * | 2015-06-25 | 2018-07-10 | 株式会社国际电气通信基础技术研究所 | 基于器官间串扰系统的预测装置及预测程序 |
| JP7028763B2 (ja) | 2015-08-14 | 2022-03-02 | コーニンクレッカ フィリップス エヌ ヴェ | 標的遺伝子発現の数学的モデリングを使用するＮＦｋＢ細胞シグナリング経路活性の評価 |
| JP6332780B2 (ja) | 2016-03-29 | 2018-05-30 | 株式会社国際電気通信基礎技術研究所 | 医薬組成物又は食品組成物、及び有効成分の体内での効果の評価方法 |
| JP6432962B2 (ja) | 2016-03-29 | 2018-12-05 | 株式会社国際電気通信基礎技術研究所 | 腎機能低下、慢性腎疾患及び腎不全からなる群から選択される少なくとも一種の疾患を予防、又は治療するための有効成分の候補物質のスクリーニング方法 |
| BR112018073014A2 (pt) | 2016-05-10 | 2019-02-19 | Mayo Foundation For Medical Education And Research | métodos e materiais para estadiamento e tratamento de câncer de pele |
| US11746381B2 (en) | 2017-03-10 | 2023-09-05 | Cancer Diagnostics Research Innvovations, LLC | Methods for diagnosing and treating gastric cancer using miRNA expression |
| WO2018224731A1 (en) * | 2017-06-05 | 2018-12-13 | Ls Cancerdiag Oy | A method for determining whether a subject is at risk to develop cancer and tools related thereto |
| EP3461915A1 (en) | 2017-10-02 | 2019-04-03 | Koninklijke Philips N.V. | Assessment of jak-stat1/2 cellular signaling pathway activity using mathematical modelling of target gene expression |
| EP3461916A1 (en) | 2017-10-02 | 2019-04-03 | Koninklijke Philips N.V. | Assessment of jak-stat3 cellular signaling pathway activity using mathematical modelling of target gene expression |
| EP3502279A1 (en) | 2017-12-20 | 2019-06-26 | Koninklijke Philips N.V. | Assessment of mapk-ap 1 cellular signaling pathway activity using mathematical modelling of target gene expression |
| JP7027179B2 (ja) * | 2018-01-24 | 2022-03-01 | キヤノン株式会社 | 給送回転体、シート給送装置及び画像形成装置 |
| WO2019173647A1 (en) | 2018-03-08 | 2019-09-12 | University Of Notre Dame Du Lac | Products for assessing colorectal cancer molecular subtype and risk of recurrence and for determining and adminstering treatment protocols based thereon |
| KR102007450B1 (ko) * | 2018-05-31 | 2019-08-05 | 한국과학기술연구원 | 대장암 치료제 발굴을 위한 신규 표적 치료 작용점의 스크리닝 방법 및 이를 이용하여 선별한 대장암 치료 예후 바이오마커 |
| CA3107401A1 (en) | 2018-07-25 | 2020-01-30 | Skylinedx B.V. | Gene signatures for predicting metastasis of melanoma and patient prognosis |
| US12370240B2 (en) | 2018-11-28 | 2025-07-29 | Genascence Corporation | Methods and compositions for treating osteoarthritis |
| WO2020123699A1 (en) * | 2018-12-11 | 2020-06-18 | The Trustees Of Columbia University In The City Of New York | Compounds and compositions that cause mycn and/or cmyc degradation and methods of use thereof |
| CN110257518B (zh) * | 2019-07-01 | 2022-08-02 | 复旦大学附属中山医院 | 一种用于预测转移性结直肠癌转化治疗疗效的基因集 |
| US12057959B2 (en) * | 2019-12-31 | 2024-08-06 | Mcafee, Llc | Device identification |
| KR102263984B1 (ko) * | 2020-02-21 | 2021-06-11 | 재단법인 아산사회복지재단 | 직장암 환자에서 수술-전 화학방사선치료의 반응을 예측하기 위한 분석방법 |
| KR102535150B1 (ko) * | 2020-04-14 | 2023-05-23 | 주식회사 베르티스 | 암의 예후 예측용 조성물 |
| EP4143309A4 (en) * | 2020-04-29 | 2025-01-01 | Freenome Holdings, Inc. | Rna markers and methods for identifying colon cell proliferative disorders |
| GB202010970D0 (en) | 2020-07-16 | 2020-09-02 | Immunovia Ab | Methods, arrays and uses thereof |
| CN112322730B (zh) * | 2020-10-16 | 2023-04-18 | 上海市第一人民医院 | 预测肿瘤耐药、复发的标志物kifc1及其抑制剂和应用 |
| EP4026918A1 (en) * | 2021-01-12 | 2022-07-13 | Koninklijke Philips N.V. | Prediction of an outcome of a colorectal cancer subject |
| CN113667673B (zh) * | 2021-07-15 | 2024-02-06 | 武汉血液中心 | 一种类孟买血型FUT1 236delG等位基因及其检测方法和应用 |
| KR20230059642A (ko) * | 2021-10-26 | 2023-05-03 | 사회복지법인 삼성생명공익재단 | miRNA를 포함하는 대장암의 치료 및 전이 억제용 조성물 및 이의 용도 |
| CN116735874B (zh) * | 2022-03-11 | 2025-09-23 | 上海市免疫学研究所 | 结直肠癌肿瘤边界细胞亚群标志物组合及其应用 |
| WO2024035653A1 (en) * | 2022-08-06 | 2024-02-15 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Predictive biomarker in avastin in colon cancer |
Family Cites Families (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020172987A1 (en) | 1998-02-12 | 2002-11-21 | Terstappen Leon W.M.M. | Methods and reagents for the rapid and efficient isolation of circulating cancer cells |
| CA2330929A1 (en) | 1998-06-06 | 1999-12-16 | Genostic Pharma Limited | Probes used for genetic profiling |
| AU4158799A (en) | 1998-06-06 | 1999-12-30 | Genostic Pharma Limited | Probes used for genetic filing |
| EP1131470A4 (en) | 1998-10-28 | 2004-11-10 | Vysis Inc | CELLULAR NETWORKS AND METHODS FOR DETECTION AND USE OF GENETIC DISORDER MARKERS |
| EP0999016B1 (en) * | 1998-11-06 | 2001-07-11 | Temco S. R. L. | Cutter for cross cutting of webs |
| US6960439B2 (en) | 1999-06-28 | 2005-11-01 | Source Precision Medicine, Inc. | Identification, monitoring and treatment of disease and characterization of biological condition using gene expression profiles |
| US6692916B2 (en) | 1999-06-28 | 2004-02-17 | Source Precision Medicine, Inc. | Systems and methods for characterizing a biological condition or agent using precision gene expression profiles |
| AU7721500A (en) | 1999-09-29 | 2001-04-30 | Human Genome Sciences, Inc. | Colon and colon cancer associated polynucleotides and polypeptides |
| CA2390687A1 (en) | 1999-12-10 | 2001-06-14 | Whitehead Institute For Biomedical Research | Metastasis genes and uses thereof |
| US7029677B2 (en) * | 2000-01-25 | 2006-04-18 | Nuvelo, Inc. | Methods of therapy and diagnosis using immunotargeting of CD84Hy1-expressing cells |
| AU2001276331A1 (en) | 2000-04-06 | 2001-10-23 | Epigenomics Ag | Diagnosis of diseases associated with metastasis |
| WO2005000087A2 (en) | 2003-06-03 | 2005-01-06 | Chiron Corporation | Gene products differentially expressed in cancerous colon cells and their methods of use ii |
| WO2002012280A2 (en) | 2000-08-03 | 2002-02-14 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of colon cancer |
| US20030166064A1 (en) | 2000-08-03 | 2003-09-04 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of colon cancer |
| WO2002012328A2 (en) | 2000-08-03 | 2002-02-14 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of colon cancer |
| US20030077568A1 (en) | 2000-09-15 | 2003-04-24 | Gish Kurt C. | Methods of diagnosis of colorectal cancer, compositions and methods of screening for colorectal cancer modulators |
| US7105293B2 (en) | 2000-09-19 | 2006-09-12 | Whitehead Institute For Biomedical Research | Genetic markers for tumors |
| AU2002246519A1 (en) | 2000-11-20 | 2002-08-06 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of colon cancer |
| WO2002074156A2 (en) * | 2001-02-02 | 2002-09-26 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of colon cancer |
| JP2005520483A (ja) * | 2001-05-09 | 2005-07-14 | ユニバーシティ ホスピタルズ オブ クリーブランド | 新規遺伝子マーカーを用いる皮膚に対する紫外線損傷の評価、それに関連する方法及び組成物 |
| US20030148314A1 (en) * | 2001-08-01 | 2003-08-07 | Millennium Pharmaceuticals, Inc. | Compositions, kits, and methods for identification, assessment, prevention, and therapy of colon cancer |
| US7622260B2 (en) | 2001-09-05 | 2009-11-24 | The Brigham And Women's Hospital, Inc. | Diagnostic and prognostic tests |
| US6964850B2 (en) | 2001-11-09 | 2005-11-15 | Source Precision Medicine, Inc. | Identification, monitoring and treatment of disease and characterization of biological condition using gene expression profiles |
| WO2003041562A2 (en) | 2001-11-14 | 2003-05-22 | Whitehead Institute For Biomedical Research | Molecular cancer diagnosis using tumor gene expression signature |
| US20030148410A1 (en) * | 2001-12-10 | 2003-08-07 | Millennium Pharmaceuticals, Inc. | Novel genes, compositions, kits, and methods for identification, assessment, prevention, and therapy of colon cancer |
| US20060046249A1 (en) | 2002-01-18 | 2006-03-02 | Fei Huang | Identification of polynucleotides and polypetide for predicting activity of compounds that interact with protein tyrosine kinase and or protein tyrosine kinase pathways |
| US7955800B2 (en) | 2002-06-25 | 2011-06-07 | Advpharma Inc. | Metastasis-associated gene profiling for identification of tumor tissue, subtyping, and prediction of prognosis of patients |
| EP1552293A4 (en) | 2002-09-10 | 2006-12-06 | Guennadi V Glinskii | METHOD FOR SEGREGATION OF GENES AND CLASSIFICATION OF BIOLOGICAL SAMPLES |
| WO2004110345A2 (en) | 2002-10-29 | 2004-12-23 | Pharmacia Corporation | Differentially expressed genes involved in cancer, the polypeptides encoded thereby, and methods of using the same |
| CA2516553C (en) | 2003-02-20 | 2013-04-16 | Genomic Health, Inc. | Use of intronic rna to measure gene expression |
| EP1644858B1 (en) | 2003-07-10 | 2017-12-06 | Genomic Health, Inc. | Expression profile algorithm and test for cancer prognosis |
| US20050014165A1 (en) | 2003-07-18 | 2005-01-20 | California Pacific Medical Center | Biomarker panel for colorectal cancer |
| WO2005015236A2 (en) | 2003-07-18 | 2005-02-17 | Roche Diagnostics Gmbh | A method for predicting the progression of adenocarcinoma |
| CA2533803A1 (en) * | 2003-07-29 | 2005-02-10 | Bristol-Myers Squibb Company | Biomarkers of cyclin-dependent kinase modulation |
| EP1522594A3 (en) | 2003-10-06 | 2005-06-22 | Bayer HealthCare AG | Methods and kits for investigating cancer |
| WO2005076005A2 (en) | 2004-01-30 | 2005-08-18 | Medizinische Universität Wien | A method for classifying a tumor cell sample based upon differential expression of at least two genes |
| US20060195266A1 (en) | 2005-02-25 | 2006-08-31 | Yeatman Timothy J | Methods for predicting cancer outcome and gene signatures for use therein |
| CA2562835A1 (en) | 2004-04-16 | 2005-10-27 | Monash University | A method for monitoring the progress of cancer |
| WO2006010150A2 (en) | 2004-07-15 | 2006-01-26 | University Of Utah Research Foundation | Housekeeping genes and methods for identifying the same |
| US20060183893A1 (en) | 2005-01-25 | 2006-08-17 | North Don A | Nucleic acids for apoptosis of cancer cells |
| JP2008535853A (ja) | 2005-04-07 | 2008-09-04 | ノバルティス ヴァクシンズ アンド ダイアグノスティクス インコーポレイテッド | 癌関連遺伝子 |
| WO2006138275A2 (en) | 2005-06-13 | 2006-12-28 | The Regents Of The University Of Michigan | Compositions and methods for treating and diagnosing cancer |
| EP1954708A4 (en) | 2005-11-23 | 2009-05-13 | Univ Utah Res Found | Methods and compositions involving intrinsic genes |
| US20090215054A1 (en) | 2005-12-13 | 2009-08-27 | Carter Scott L | Prognosis indicators for solid human tumors |
| NZ544432A (en) | 2005-12-23 | 2009-07-31 | Pacific Edge Biotechnology Ltd | Prognosis prediction for colorectal cancer using a prognositc signature comprising markers ME2 and FAS |
| KR20090003178A (ko) | 2006-01-11 | 2009-01-09 | 게노믹 헬쓰, 인코포레이티드 | 직장결장암 예후에 대한 유전자 발현 마커 |
| WO2007112330A2 (en) | 2006-03-24 | 2007-10-04 | Diadexus, Inc. | Compositions and methods for detection, prognosis and treatment of colon cancer |
| CA2680591A1 (en) | 2007-03-15 | 2008-09-25 | Genomic Health, Inc. | Gene expression markers for prediction of patient response to chemotherapy |
| US8067178B2 (en) | 2008-03-14 | 2011-11-29 | Genomic Health, Inc. | Gene expression markers for prediction of patient response to chemotherapy |
| US8765383B2 (en) | 2009-04-07 | 2014-07-01 | Genomic Health, Inc. | Methods of predicting cancer risk using gene expression in premalignant tissue |
| WO2010127322A1 (en) | 2009-05-01 | 2010-11-04 | Genomic Health Inc. | Gene expression profile algorithm and test for likelihood of recurrence of colorectal cancer and response to chemotherapy |
-
2007
- 2007-01-11 KR KR1020087019544A patent/KR20090003178A/ko not_active Withdrawn
- 2007-01-11 NZ NZ593224A patent/NZ593224A/xx unknown
- 2007-01-11 EP EP10194720.8A patent/EP2412824B1/en not_active Not-in-force
- 2007-01-11 EP EP10194722A patent/EP2400036A1/en not_active Withdrawn
- 2007-01-11 ES ES07717900.0T patent/ES2491222T3/es active Active
- 2007-01-11 EP EP10194713A patent/EP2412820A1/en not_active Withdrawn
- 2007-01-11 NZ NZ593225A patent/NZ593225A/xx unknown
- 2007-01-11 MX MX2008008973A patent/MX2008008973A/es active IP Right Grant
- 2007-01-11 EP EP10177406.5A patent/EP2377950B1/en not_active Not-in-force
- 2007-01-11 NZ NZ569788A patent/NZ569788A/en unknown
- 2007-01-11 NZ NZ593228A patent/NZ593228A/xx unknown
- 2007-01-11 US US11/653,102 patent/US7695913B2/en active Active
- 2007-01-11 EP EP07717900.0A patent/EP1974058B1/en active Active
- 2007-01-11 JP JP2008550454A patent/JP5297202B2/ja active Active
- 2007-01-11 EP EP10194717A patent/EP2412822A1/en not_active Withdrawn
- 2007-01-11 WO PCT/US2007/000995 patent/WO2007082099A2/en not_active Ceased
- 2007-01-11 NZ NZ593227A patent/NZ593227A/xx unknown
- 2007-01-11 BR BRPI0706511-6A patent/BRPI0706511A2/pt not_active IP Right Cessation
- 2007-01-11 NZ NZ593229A patent/NZ593229A/xx unknown
- 2007-01-11 EP EP10194719.0A patent/EP2412823B1/en not_active Not-in-force
- 2007-01-11 EP EP10194714.1A patent/EP2412821B1/en not_active Not-in-force
- 2007-01-11 EP EP10194715A patent/EP2407553A1/en not_active Withdrawn
- 2007-01-11 DK DK07717900.0T patent/DK1974058T3/da active
- 2007-01-11 NZ NZ593226A patent/NZ593226A/xx unknown
- 2007-01-11 CA CA002636984A patent/CA2636984A1/en not_active Abandoned
- 2007-01-11 AU AU2007204826A patent/AU2007204826B2/en active Active
-
2008
- 2008-07-13 IL IL192794A patent/IL192794A/en active IP Right Grant
- 2008-08-08 NO NO20083461A patent/NO20083461L/no not_active Application Discontinuation
-
2010
- 2010-01-29 US US12/696,934 patent/US8153378B2/en active Active
- 2010-10-25 US US12/911,551 patent/US8026060B2/en active Active
- 2010-10-25 US US12/911,532 patent/US8029995B2/en active Active
- 2010-10-25 US US12/911,544 patent/US8153380B2/en active Active
- 2010-10-25 US US12/911,519 patent/US8273537B2/en active Active
- 2010-10-25 US US12/911,526 patent/US8153379B2/en active Active
-
2011
- 2011-01-19 US US13/009,733 patent/US8198024B2/en active Active
-
2012
- 2012-03-06 US US13/413,338 patent/US8367345B2/en active Active
- 2012-12-13 JP JP2012272400A patent/JP5486664B2/ja active Active
- 2012-12-28 US US13/729,462 patent/US20130102492A1/en not_active Abandoned
-
2013
- 2013-06-13 JP JP2013124950A patent/JP5486719B2/ja active Active
- 2013-06-13 JP JP2013124949A patent/JP5486718B2/ja active Active
- 2013-06-13 JP JP2013124951A patent/JP5486720B2/ja active Active
- 2013-06-13 JP JP2013124952A patent/JP2013215201A/ja active Pending
- 2013-06-13 JP JP2013124948A patent/JP5486717B2/ja active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5486664B2 (ja) | 結腸直腸癌の予後のための遺伝子発現マーカー | |
| JP6351112B2 (ja) | 前立腺癌の予後を定量化するための遺伝子発現プロフィールアルゴリズムおよび試験 | |
| JP6190434B2 (ja) | 化学療法剤に対する応答を予測するための遺伝子発現マーカー | |
| JP4680898B2 (ja) | 癌再発の可能性の予測 | |
| JP6246845B2 (ja) | 遺伝子発現を用いた前立腺癌の予後を定量化する方法 | |
| US8632980B2 (en) | Gene expression markers for prediction of patient response to chemotherapy | |
| US20110123990A1 (en) | Methods To Predict Clinical Outcome Of Cancer | |
| WO2008115419A2 (en) | Gene expression markers for prediction of patient response to chemotherapy | |
| JP2012525159A (ja) | 結腸直腸癌の再発および化学療法に対する応答の可能性における遺伝子発現プロファイルアルゴリズムおよび試験 | |
| JP2007507222A (ja) | 化学療法に対する応答を予測するための遺伝子発現マーカー | |
| CN101400804B (zh) | 用于结肠直肠癌预后的基因表达标志物 | |
| US20110287958A1 (en) | Method for Using Gene Expression to Determine Colorectal Tumor Stage | |
| HK40014990A (en) | Methods to predict clinical outcome of cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 9A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2342 DE 24-11-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |